The Prognostic and Therapeutic Potential of Fragile X Mental Retardation 1 () Gene Expression in Prostate Adenocarcinoma: Insights into Survival Outcomes and Oncogenic Pathway Modulation.

Prostate adenocarcinoma (PRAD) is the second most common tumor associated with death. The role and mechanisms of the fragile X mental retardation 1 () gene in PRAD remain unknown. We conducted an analysis of expression in PRAD to determine its prognostic importance and connection to carcinogenic pathways such as . Survival analyses were utilized to establish a correlation between expression and patient outcomes. We used the integration of genomic data with bioinformatic predictions to predict the regulatory factors of the gene in PRAD. Our data revealed that individuals with higher levels of expression experience worse survival outcomes compared to those with lower expression (hazard ratio [HR] = 5.08, 95% confidence interval [CI] = 1.07 - 24, = 0.0412). expression was significantly higher in patients with advanced pathological tumor stages, particularly in the pT3 and pT4 combined stages and the pN1 nodal stage. Furthermore, patients with high Gleason scores (GSs) (combined GSs 8 and 9) exhibited increased levels of expression. Our results further identify a possible regulatory link between and key oncogenic pathways, including , and predict the possible mechanism by which is regulated in PRAD. Our data suggest that the gene could serve as a biomarker for PRAD progression. However, in-depth investigations, including those with large patient samples and in vitro studies, are needed to validate this finding and understand the mechanisms involved.